Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The company's CT-388 dual agonist and CT-996 oral formulation are progressing through Phase II trials, with potential market entry expected by 2029
Retatrutide activates all three: GLP-1, GIP, and glucagon
"Melanocortin receptors, melanotropic peptides and penile erection"
The darkening of freckles is a normal and expected part of the journey
US$ 27.48
US$ 26.16
US$ 25.09
US$ 27.58
US$ 28.99
US$ 29.40
US$ 24.32
US$ 29.34
US$ 22.44
US$ 21.82
.webp)
US$ 23.23
US$ 20.60
US$ 28.19
